Cite
Comprehensive In Vitro Proarrhythmia Assay (CiPA) Update from a Cardiac Safety Research Consortium / Health and Environmental Sciences Institute / FDA Meeting
MLA
Strauss, David G., et al. “Comprehensive In Vitro Proarrhythmia Assay (CiPA) Update from a Cardiac Safety Research Consortium / Health and Environmental Sciences Institute / FDA Meeting.” Therapeutic Innovation and Regulatory Science, vol. 53, no. 4, July 2019, pp. 519–25. EBSCOhost, https://doi.org/10.1177/2168479018795117.
APA
Strauss, D. G., Gintant, G., Li, Z., Wu, W., Blinova, K., Vicente, J., Turner, J. R., & Sager, P. T. (2019). Comprehensive In Vitro Proarrhythmia Assay (CiPA) Update from a Cardiac Safety Research Consortium / Health and Environmental Sciences Institute / FDA Meeting. Therapeutic Innovation and Regulatory Science, 53(4), 519–525. https://doi.org/10.1177/2168479018795117
Chicago
Strauss, David G., Gary Gintant, Zhihua Li, Wendy Wu, Ksenia Blinova, Jose Vicente, J. Rick Turner, and Philip T. Sager. 2019. “Comprehensive In Vitro Proarrhythmia Assay (CiPA) Update from a Cardiac Safety Research Consortium / Health and Environmental Sciences Institute / FDA Meeting.” Therapeutic Innovation and Regulatory Science 53 (4): 519–25. doi:10.1177/2168479018795117.